HM15211
Sources
registry, as of 2025-01-27Stale
https://clinicaltrials.gov/study/NCT03744182
A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD. Overall status COMPLETED. Phases PHASE1. Lead sponsor Hanmi Pharmaceutical Company Limited. Enrollment 66. Conditions NAFLD. This study is a phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HM15211 in obese subjects with NAFLD deaths 0.01 mg/kg HM15211 0 nausea 0.01 mg/kg HM15211 1 vomiting 0.01 mg/kg HM15211 1 deaths 0.02 mg/kg HM15211 0 nausea 0.02 mg/kg HM15211 1 vomiting 0.02 mg/kg HM15211 0 deaths 0.04 mg/kg HM15211 0 nausea 0.04 mg/kg HM15211 2 vomiting 0.04 mg/kg HM15211 0 deaths 0.06 mg/kg HM15211 0 nausea 0.06 mg/kg HM15211 3 vomiting 0.06 mg/kg HM15211 1
ClinicalTrials.gov NCT03744182 protocol and results modules
registry, as of 2025-02-06Stale
https://clinicaltrials.gov/study/NCT03374241
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide). Overall status COMPLETED. Phases PHASE1. Lead sponsor Hanmi Pharmaceutical Company Limited. Enrollment 41. Conditions Obesity. Single ascending dose of HM15211 in healthy obese subjects. deaths Cohort 1 Active 0 deaths Cohort 2 Active 0 deaths Cohort 3 Active 0 deaths Cohort 4 Active 0 deaths Cohort 5 Active 0
ClinicalTrials.gov NCT03374241 protocol and results modules